These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
166 related articles for article (PubMed ID: 21081474)
1. 2-Tellurium-bridged β-cyclodextrin, a thioredoxin reductase inhibitor, sensitizes human breast cancer cells to TRAIL-induced apoptosis through DR5 induction and NF-κB suppression. Lin T; Ding Z; Li N; Xu J; Luo G; Liu J; Shen J Carcinogenesis; 2011 Feb; 32(2):154-67. PubMed ID: 21081474 [TBL] [Abstract][Full Text] [Related]
2. Novel insights into the synergistic interaction of a thioredoxin reductase inhibitor and TRAIL: the activation of the ASK1-ERK-Sp1 pathway. Lin T; Chen Y; Ding Z; Luo G; Liu J; Shen J PLoS One; 2013; 8(5):e63966. PubMed ID: 23696862 [TBL] [Abstract][Full Text] [Related]
3. Synthetic triterpenoids cooperate with tumor necrosis factor-related apoptosis-inducing ligand to induce apoptosis of breast cancer cells. Hyer ML; Croxton R; Krajewska M; Krajewski S; Kress CL; Lu M; Suh N; Sporn MB; Cryns VL; Zapata JM; Reed JC Cancer Res; 2005 Jun; 65(11):4799-808. PubMed ID: 15930300 [TBL] [Abstract][Full Text] [Related]
4. Butein sensitizes human hepatoma cells to TRAIL-induced apoptosis via extracellular signal-regulated kinase/Sp1-dependent DR5 upregulation and NF-kappaB inactivation. Moon DO; Kim MO; Choi YH; Kim GY Mol Cancer Ther; 2010 Jun; 9(6):1583-95. PubMed ID: 20515942 [TBL] [Abstract][Full Text] [Related]
5. Nuclear factor-kappaB maintains TRAIL resistance in human pancreatic cancer cells. Khanbolooki S; Nawrocki ST; Arumugam T; Andtbacka R; Pino MS; Kurzrock R; Logsdon CD; Abbruzzese JL; McConkey DJ Mol Cancer Ther; 2006 Sep; 5(9):2251-60. PubMed ID: 16985059 [TBL] [Abstract][Full Text] [Related]
6. Suberoylanilide hydroxamic acid (Zolinza/vorinostat) sensitizes TRAIL-resistant breast cancer cells orthotopically implanted in BALB/c nude mice. Shankar S; Davis R; Singh KP; Kurzrock R; Ross DD; Srivastava RK Mol Cancer Ther; 2009 Jun; 8(6):1596-605. PubMed ID: 19509267 [TBL] [Abstract][Full Text] [Related]
7. OSMI-1 Enhances TRAIL-Induced Apoptosis through ER Stress and NF-κB Signaling in Colon Cancer Cells. Lee SJ; Lee DE; Choi SY; Kwon OS Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681736 [TBL] [Abstract][Full Text] [Related]
8. Inhibition of ataxia telangiectasia mutated kinase activity enhances TRAIL-mediated apoptosis in human melanoma cells. Ivanov VN; Zhou H; Partridge MA; Hei TK Cancer Res; 2009 Apr; 69(8):3510-9. PubMed ID: 19351839 [TBL] [Abstract][Full Text] [Related]
9. Suppression of HSP70 expression sensitizes NSCLC cell lines to TRAIL-induced apoptosis by upregulating DR4 and DR5 and downregulating c-FLIP-L expressions. Zhuang H; Jiang W; Zhang X; Qiu F; Gan Z; Cheng W; Zhang J; Guan S; Tang B; Huang Q; Wu X; Huang X; Jiang W; Hu Q; Lu M; Hua ZC J Mol Med (Berl); 2013 Feb; 91(2):219-35. PubMed ID: 22948392 [TBL] [Abstract][Full Text] [Related]
10. Inhibition of Yin Yang 1-dependent repressor activity of DR5 transcription and expression by the novel proteasome inhibitor NPI-0052 contributes to its TRAIL-enhanced apoptosis in cancer cells. Baritaki S; Suzuki E; Umezawa K; Spandidos DA; Berenson J; Daniels TR; Penichet ML; Jazirehi AR; Palladino M; Bonavida B J Immunol; 2008 May; 180(9):6199-210. PubMed ID: 18424742 [TBL] [Abstract][Full Text] [Related]
11. MS-275 sensitizes TRAIL-resistant breast cancer cells, inhibits angiogenesis and metastasis, and reverses epithelial-mesenchymal transition in vivo. Srivastava RK; Kurzrock R; Shankar S Mol Cancer Ther; 2010 Dec; 9(12):3254-66. PubMed ID: 21041383 [TBL] [Abstract][Full Text] [Related]
12. Aspirin sensitizes cancer cells to TRAIL-induced apoptosis by reducing survivin levels. Lu M; Strohecker A; Chen F; Kwan T; Bosman J; Jordan VC; Cryns VL Clin Cancer Res; 2008 May; 14(10):3168-76. PubMed ID: 18483385 [TBL] [Abstract][Full Text] [Related]
13. Down-regulation of Cbl-b by bufalin results in up-regulation of DR4/DR5 and sensitization of TRAIL-induced apoptosis in breast cancer cells. Yan S; Qu X; Xu C; Zhu Z; Zhang L; Xu L; Song N; Teng Y; Liu Y J Cancer Res Clin Oncol; 2012 Aug; 138(8):1279-89. PubMed ID: 22447040 [TBL] [Abstract][Full Text] [Related]
14. Nitric Oxide Inhibits NF-κB-mediated Survival Signaling: Possible Role in Overcoming TRAIL Resistance. Bauer JA; Lupica JA; Didonato JA; Lindner DJ Anticancer Res; 2020 Dec; 40(12):6751-6763. PubMed ID: 33288568 [TBL] [Abstract][Full Text] [Related]
15. Proteasome inhibitors enhance TRAIL-induced apoptosis through the intronic regulation of DR5: involvement of NF-kappa B and reactive oxygen species-mediated p53 activation. Chen JJ; Chou CW; Chang YF; Chen CC J Immunol; 2008 Jun; 180(12):8030-9. PubMed ID: 18523266 [TBL] [Abstract][Full Text] [Related]
16. Caspase cleavage product lacking amino-terminus of IkappaBalpha sensitizes resistant cells to TNF-alpha and TRAIL-induced apoptosis. Kim KW; Kim BJ; Chung CW; Jo DG; Kim IK; Song YH; Kwon YK; Woo HN; Jung YK J Cell Biochem; 2002; 85(2):334-45. PubMed ID: 11948689 [TBL] [Abstract][Full Text] [Related]
17. BAY61-3606 potentiates the anti-tumor effects of TRAIL against colon cancer through up-regulating DR4 and down-regulating NF-κB. Du J; Wang Y; Chen D; Ji G; Ma Q; Liao S; Zheng Y; Zhang J; Hou Y Cancer Lett; 2016 Dec; 383(2):145-153. PubMed ID: 27721019 [TBL] [Abstract][Full Text] [Related]
18. 3‑Bromopyruvate sensitizes human breast cancer cells to TRAIL‑induced apoptosis via the phosphorylated AMPK‑mediated upregulation of DR5. Chen Y; Wei L; Zhang X; Liu X; Chen Y; Zhang S; Zhou L; Li Q; Pan Q; Zhao S; Liu H Oncol Rep; 2018 Nov; 40(5):2435-2444. PubMed ID: 30132536 [TBL] [Abstract][Full Text] [Related]
19. Short-hairpin RNA-induced suppression of adenine nucleotide translocase-2 in breast cancer cells restores their susceptibility to TRAIL-induced apoptosis by activating JNK and modulating TRAIL receptor expression. Jang JY; Jeon YK; Choi Y; Kim CW Mol Cancer; 2010 Sep; 9():262. PubMed ID: 20875141 [TBL] [Abstract][Full Text] [Related]
20. beta-Ionone enhances TRAIL-induced apoptosis in hepatocellular carcinoma cells through Sp1-dependent upregulation of DR5 and downregulation of NF-kappaB activity. Kim MO; Moon DO; Kang CH; Kwon TK; Choi YH; Kim GY Mol Cancer Ther; 2010 Apr; 9(4):833-43. PubMed ID: 20354117 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]